300439 美康生物
已收盘 08-28 15:00:00
资讯
新帖
简况
美康生物(300439)6月30日股东户数2.12万户，较上期减少11%
证券之星 · 17:17
美康生物(300439)6月30日股东户数2.12万户，较上期减少11%
图解美康生物中报：第二季度单季净利润同比增长6.61%
证券之星 · 03:15
图解美康生物中报：第二季度单季净利润同比增长6.61%
美康生物：2026年上半年净利润6194.92万元，同比增长9.00%
格隆汇 · 08-28 18:00
美康生物：2026年上半年净利润6194.92万元，同比增长9.00%
美康生物（300439）披露部分限制性股票回购注销完成公告，8月13日股价上涨1.42%
证券之星 · 08-13
美康生物（300439）披露部分限制性股票回购注销完成公告，8月13日股价上涨1.42%
股市必读：美康生物（300439）6月26日董秘有最新回复
证券之星 · 06-29
股市必读：美康生物（300439）6月26日董秘有最新回复
美康生物（300439）披露关于使用部分闲置募集资金进行现金管理的公告，6月1日股价上涨1.53%
证券之星 · 06-01
美康生物（300439）披露关于使用部分闲置募集资金进行现金管理的公告，6月1日股价上涨1.53%
美康生物（300439）披露2025年年度股东会决议公告，5月22日股价下跌0.32%
证券之星 · 05-22
美康生物（300439）披露2025年年度股东会决议公告，5月22日股价下跌0.32%
美康生物（300439）披露2025年年度股东会召开提示性公告，5月20日股价下跌1.89%
证券之星 · 05-20
美康生物（300439）披露2025年年度股东会召开提示性公告，5月20日股价下跌1.89%
每周股票复盘：美康生物（300439）2025年净利降75.5%
证券之星 · 05-03
每周股票复盘：美康生物（300439）2025年净利降75.5%
股市必读：美康生物年报 - 第四季度单季净利润同比下降92.07%
证券之星 · 04-30
股市必读：美康生物年报 - 第四季度单季净利润同比下降92.07%
美康生物（300439）2026年一季报简析：营收净利润同比双双增长，公司应收账款体量较大
证券之星 · 04-30
美康生物（300439）2026年一季报简析：营收净利润同比双双增长，公司应收账款体量较大
美康生物：聚焦中东、东南亚、南美等战略市场
证券之星 · 04-29
美康生物：聚焦中东、东南亚、南美等战略市场
美康生物(300439.SZ)发布一季度业绩，归母净利润3376.64万元，增长11.08%
智通财经 · 04-28
美康生物(300439.SZ)发布一季度业绩，归母净利润3376.64万元，增长11.08%
美康生物(300439.SZ)取得一项医疗器械注册证
智通财经 · 04-03
美康生物(300439.SZ)取得一项医疗器械注册证
美康生物：受体外诊断行业政策影响，公司主营产品面临阶段性量价压力
证券之星 · 03-13
美康生物：受体外诊断行业政策影响，公司主营产品面临阶段性量价压力
美康生物收盘下跌1.32%，滚动市盈率17.21倍，总市值43.19亿元
金融界 · 2025-03-11
美康生物收盘下跌1.32%，滚动市盈率17.21倍，总市值43.19亿元
美康生物：公司主要从事体外诊断产品的研发、生产和销售及体外诊断产品的代理业务
证券之星 · 2025-03-11
美康生物：公司主要从事体外诊断产品的研发、生产和销售及体外诊断产品的代理业务
美康生物收盘上涨1.52%，滚动市盈率17.36倍，总市值43.58亿元
金融界 · 2025-03-06
美康生物收盘上涨1.52%，滚动市盈率17.36倍，总市值43.58亿元
美康生物(300439.SZ)及江西美康各取得一项医疗器械注册证
智通财经 · 2025-03-03
美康生物(300439.SZ)及江西美康各取得一项医疗器械注册证
美康生物：公司通过收购取得VAP/VLP血脂亚组分检测技术后在国内进行技术转化和本土化推广
证券之星 · 2025-02-18
美康生物：公司通过收购取得VAP/VLP血脂亚组分检测技术后在国内进行技术转化和本土化推广
加载更多
公司概况
公司名称：
美康生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2015-04-22
主营业务：
美康生物科技股份有限公司的主营业务是体外诊断产品的研发、生产和销售及体外诊断产品的代理业务，并提供第三方医学诊断服务。公司的主要产品是体外诊断试剂及仪器、第三方医学诊断服务、智慧实验室整体解决方案。
发行价格：
27.51
{"stockData":{"symbol":"300439","market":"SZ","secType":"STK","nameCN":"美康生物","latestPrice":9.37,"timestamp":1787900610000,"preClose":9.4,"halted":0,"volume":2656200,"delay":0,"changeRate":-0.0032,"floatShares":292000000,"shares":384000000,"eps":0.178,"marketStatus":"已收盘","change":-0.03,"latestTime":"08-28 15:00:00","open":9.4,"high":9.47,"low":9.33,"amount":24982200,"amplitude":0.0149,"askPrice":9.38,"askSize":44,"bidPrice":9.37,"bidSize":76,"shortable":0,"etf":0,"ttmEps":0.178,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":5,"adr":0,"adjPreClose":9.4,"symbolType":"stock","openAndCloseTimeList":[[1787880600000,1787887800000],[1787893200000,1787900400000]],"highLimit":10.34,"lowLimit":8.46,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":383843815,"isCdr":false,"pbRate":1.21,"roa":"--","peRate":52.640449,"roe":"1.14%","epsLYR":0.16,"committee":-0.109941,"marketValue":3597000000,"turnoverRate":0.0091,"status":1,"floatMarketCap":2739000000},"requestUrl":"/m/hq/s/300439","defaultTab":"news","newsList":[{"id":"2663012905","title":"美康生物(300439)6月30日股东户数2.12万户，较上期减少11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663012905","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663012905?lang=zh_cn&edition=full","pubTime":"2026-08-29 17:17","pubTimestamp":1787995059,"startTime":"0","endTime":"0","summary":"证券之星消息，近日美康生物披露，截至2026年6月30日公司股东户数为2.12万户，较3月31日减少2617.0户，减幅为11.0%。在医疗器械行业个股中，美康生物股东户数高于行业平均水平，截至6月30日，医疗器械行业平均股东户数为2.09万户。从股价来看，2026年3月31日至2026年6月30日，美康生物区间跌幅为16.5%，在此期间股东户数减少2617.0户，减幅为11.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900023804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300439","BK0042","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013853","title":"图解美康生物中报：第二季度单季净利润同比增长6.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013853","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663013853?lang=zh_cn&edition=full","pubTime":"2026-08-29 03:15","pubTimestamp":1787944551,"startTime":"0","endTime":"0","summary":"证券之星消息，美康生物2026年中报显示，上半年度公司主营收入8.28亿元，同比上升12.47%；归母净利润6194.92万元，同比上升9.0%；扣非净利润4423.91万元，同比上升47.34%；其中2026年第二季度，公司单季度主营收入4.52亿元，同比上升24.8%；单季度归母净利润2818.28万元，同比上升6.61%；单季度扣非净利润2109.39万元，同比上升124.96%；负债率19.19%，投资收益969.78万元，财务费用-74.72万元，毛利率35.47%。财报数据概要请见下图:本文数据来源于美康生物2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900006995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300439"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662506932","title":"美康生物：2026年上半年净利润6194.92万元，同比增长9.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662506932","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662506932?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:00","pubTimestamp":1787911241,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0046","BK0239","BK0042","300439"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659163305","title":"美康生物（300439）披露部分限制性股票回购注销完成公告，8月13日股价上涨1.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659163305","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659163305?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:30","pubTimestamp":1786631435,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，美康生物报收于9.27元，较前一交易日上涨1.42%，最新总市值为35.63亿元。该股当日开盘9.15元，最高9.39元，最低8.98元，成交额达4832.4万元，换手率为1.79%。公告显示，公司本次回购注销47.50万股限制性股票，涉及8人，占回购前总股本的0.1236%。本次回购注销完成后，公司总股本由384,318,815股变更为383,843,815股。相关手续已于2026年8月12日完成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300039855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","300439","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647834657","title":"股市必读：美康生物（300439）6月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2647834657","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647834657?lang=zh_cn&edition=full","pubTime":"2026-06-29 05:44","pubTimestamp":1782683055,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，美康生物报收于8.01元，下跌2.2%，换手率0.83%，成交量2.42万手，成交额1958.36万元。董秘最新回复投资者： 董秘好。公司股价持续重挫，市场疑虑重重。目前公司生产经营活动一切正常，各项业务稳步推进。管理层专注于提升业绩与竞争力，以推动价值回归。公司严格按照有关法律法规及相关规定履行信息披露义务。当日关注点交易信息汇总：6月26日主力资金净流入99.32万元，游资资金净流出125.1万元，散户资金净流入25.78万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900001767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300439","BK0042","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640580859","title":"美康生物（300439）披露关于使用部分闲置募集资金进行现金管理的公告，6月1日股价上涨1.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640580859","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640580859?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:16","pubTimestamp":1780308980,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，美康生物报收于9.29元，较前一交易日上涨1.53%，最新总市值为35.7亿元。该股当日开盘9.1元，最高9.39元，最低9.02元，成交额达3572.93万元，换手率为1.33%。近日，美康生物科技股份有限公司披露《关于使用部分闲置募集资金进行现金管理的公告》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100029660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300439","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637348868","title":"美康生物（300439）披露2025年年度股东会决议公告，5月22日股价下跌0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637348868","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637348868?lang=zh_cn&edition=full","pubTime":"2026-05-22 22:32","pubTimestamp":1779460341,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，美康生物报收于9.44元，较前一交易日下跌0.32%，最新总市值为36.28亿元。该股当日开盘9.55元，最高9.58元，最低9.35元，成交额达4254.76万元，换手率为1.54%。近日，美康生物科技股份有限公司披露《2025年年度股东会决议公告》。会议召集、召开及表决程序合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200045302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300439","BK0239","BK0046","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636084357","title":"美康生物（300439）披露2025年年度股东会召开提示性公告，5月20日股价下跌1.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636084357","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636084357?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:02","pubTimestamp":1779271340,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，美康生物报收于9.84元，较前一交易日下跌1.89%，最新总市值为37.82亿元。该股当日开盘10.03元，最高10.05元，最低9.78元，成交额达3444.98万元，换手率为1.2%。美康生物科技股份有限公司于近日发布《关于召开2025年年度股东会的提示性公告》。公告显示，公司定于2026年5月22日召开2025年年度股东会，会议采取现场与网络投票相结合方式，股权登记日为2026年5月15日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000034620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0046","300439","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632677429","title":"每周股票复盘：美康生物（300439）2025年净利降75.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632677429","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632677429?lang=zh_cn&edition=full","pubTime":"2026-05-03 06:03","pubTimestamp":1777759395,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，美康生物报收于10.09元，较上周的9.7元上涨4.02%。本周，美康生物4月29日盘中最高价报10.17元。本周关注点来自业绩披露要点：美康生物2025年归母净利润6320.15万元，同比下降75.5%。股本股东变化股东户数变动截至2026年3月31日，美康生物股东户数为2.38万户，较2025年12月31日增加559户，增幅2.41%。报告供2025年年度报告披露使用。2025年年度审计报告公司发布2025年度财务报告，实现营业收入153.92亿元，归母净利润6320.15万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300439","BK0046","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631575373","title":"股市必读：美康生物年报 - 第四季度单季净利润同比下降92.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631575373","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631575373?lang=zh_cn&edition=full","pubTime":"2026-04-30 07:50","pubTimestamp":1777506627,"startTime":"0","endTime":"0","summary":"公司公告汇总2025年年度报告摘要美康生物科技股份有限公司2025年年度报告摘要显示，公司2025年实现营业收入1,539,159,714.69元，同比下降11.67%；归属于上市公司股东的净利润为63,201,459.62元，同比下降75.50%；归属于上市公司股东的扣除非经常性损益的净利润为15,456,921.15元，同比下降92.99%；经营活动产生的现金流量净额为266,614,910.95元，同比下降32.98%。2025年度内部控制审计报告立信会计师事务所对美康生物科技股份有限公司截至2025年12月31日的财务报告内部控制有效性进行了审计。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000026790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300439"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631578818","title":"美康生物（300439）2026年一季报简析：营收净利润同比双双增长，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2631578818","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631578818?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:42","pubTimestamp":1777502563,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期美康生物发布2026年一季报。截至本报告期末，公司营业总收入3.76亿元，同比上升0.53%，归母净利润3376.64万元，同比上升11.08%。本报告期美康生物公司应收账款体量较大，当期应收账款占最新年报归母净利润比达964.06%。本次财报公布的各项数据指标表现尚佳。去年的净利率为3.99%，算上全部成本后，公司产品或服务的附加值不高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000022679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300439"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631556881","title":"美康生物：聚焦中东、东南亚、南美等战略市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2631556881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631556881?lang=zh_cn&edition=full","pubTime":"2026-04-29 09:15","pubTimestamp":1777425324,"startTime":"0","endTime":"0","summary":"证券之星消息，美康生物(300439)04月28日在投资者关系平台上答复投资者关心的问题。投资者提问：您好董秘，近期中东国家加强了与中国的合作，请问公司是否有计划加大该地区的市场合作？美康生物回复：尊敬的投资者您好！公司聚焦中东、东南亚、南美等战略市场，加速海外业务拓展和品牌建设。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900028763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0046","300439","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630164302","title":"美康生物(300439.SZ)发布一季度业绩，归母净利润3376.64万元，增长11.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630164302","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630164302?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:47","pubTimestamp":1777380420,"startTime":"0","endTime":"0","summary":"智通财经APP讯，美康生物(300439.SZ)发布2026年第一季度报告，该公司营业收入为3.76亿元，同比增长0.53%。归属于上市公司股东的净利润为3376.64万元，同比增长11.08%。归属于上市公司股东的扣除非经常性损益的净利润为2314.52万元，同比增长12.09%。基本每股收益为0.09元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"美康生物(300439.SZ)发布一季度业绩，归母净利润3376.64万元，增长11.08%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300439"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624659374","title":"美康生物(300439.SZ)取得一项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2624659374","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2624659374?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:32","pubTimestamp":1775208736,"startTime":"0","endTime":"0","summary":"智通财经APP讯，美康生物(300439.SZ)公告，公司近日取得了由国家药品监督管理局颁发的医疗器械注册证，产品名称为：葡萄糖-6-磷酸脱氢酶测定试剂盒(葡萄糖-6-磷酸底物法)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425109.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","300439","159883","BK0046","BK1100","BK1574","BK1583","BK0042","09997","BK0239","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619197732","title":"美康生物：受体外诊断行业政策影响，公司主营产品面临阶段性量价压力","url":"https://stock-news.laohu8.com/highlight/detail?id=2619197732","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2619197732?lang=zh_cn&edition=full","pubTime":"2026-03-13 20:52","pubTimestamp":1773406326,"startTime":"0","endTime":"0","summary":"股价波动受公司业绩、宏观经济、行业政策、市场情绪等诸多因素影响。公司生产经营一切正常。受体外诊断行业政策影响，公司主营产品面临阶段性量价压力。公司将继续加强成本精细化管理，提升公司在生免领域的市场份额和品牌影响力，加快推进精准诊断业务及国际业务布局。并切实履行信息披露义务、加强投资者沟通，积极向市场传递公司投资价值。如有资本运作相关计划措施，公司将严格按照相关法律法规履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300038447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300439","BK0042","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518797944","title":"美康生物收盘下跌1.32%，滚动市盈率17.21倍，总市值43.19亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518797944","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518797944?lang=zh_cn&edition=full","pubTime":"2025-03-11 17:11","pubTimestamp":1741684302,"startTime":"0","endTime":"0","summary":"3月11日，美康生物今日收盘11.25元，下跌1.32%，滚动市盈率PE达到17.21倍，总市值43.19亿元。从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均47.88倍，行业中值33.61倍，美康生物排名第32位。资金流向方面，3月11日，美康生物主力资金净流出714.15万元，近5日总体呈流出状态，5日共流出862.27万元。美康生物科技股份有限公司主要从事体外诊断产品的研发、生产和销售及体外诊断产品的代理业务，并提供第三方医学诊断服务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/11171148658492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0046","BK0239","300439","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518733763","title":"美康生物：公司主要从事体外诊断产品的研发、生产和销售及体外诊断产品的代理业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2518733763","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518733763?lang=zh_cn&edition=full","pubTime":"2025-03-11 08:43","pubTimestamp":1741653788,"startTime":"0","endTime":"0","summary":"证券之星消息，美康生物(300439)03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在基因测序方面有什么发展规划？美康生物回复：尊敬的投资者您好！公司主要从事体外诊断产品的研发、生产和销售及体外诊断产品的代理业务，并提供第三方医学诊断服务。第三方医学诊断服务包括部分基因检测服务，关于公司的研发规划和业务进展请留意公司的定期报告。感谢您的关注！以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031100007764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0046","BK0239","300439"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517131415","title":"美康生物收盘上涨1.52%，滚动市盈率17.36倍，总市值43.58亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517131415","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517131415?lang=zh_cn&edition=full","pubTime":"2025-03-06 17:23","pubTimestamp":1741252995,"startTime":"0","endTime":"0","summary":"3月6日，美康生物今日收盘11.35元，上涨1.52%，滚动市盈率PE达到17.36倍，总市值43.58亿元。从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.92倍，行业中值33.55倍，美康生物排名第33位。股东方面，截至2024年9月30日，美康生物股东户数28253户，较上次增加30户，户均持股市值35.28万元，户均持股数量2.76万股。美康生物科技股份有限公司主要从事体外诊断产品的研发、生产和销售及体外诊断产品的代理业务，并提供第三方医学诊断服务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/06172348564902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","300439","BK0046","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516683367","title":"美康生物(300439.SZ)及江西美康各取得一项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2516683367","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516683367?lang=zh_cn&edition=full","pubTime":"2025-03-03 17:26","pubTimestamp":1740994010,"startTime":"0","endTime":"0","summary":"智通财经APP讯，美康生物(300439.SZ)公告，公司及控股子公司江西美康盛德生物科技有限公司(简称“江西美康”)分别取得了由浙江省药品监督管理局和江西省药品监督管理局颁发的《医疗器械注册证(体外诊断试剂)》，相关产品分别为：高敏肌钙蛋白T检测试剂盒(化学发光微粒子免疫检测法)、血管内皮生长因子检测试剂盒(化学发光免疫分析法)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1256957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1583","300439","BK1574","159883","BK0042","BK0046","BK1100","09996","BK1222","09997"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512900955","title":"美康生物：公司通过收购取得VAP/VLP血脂亚组分检测技术后在国内进行技术转化和本土化推广","url":"https://stock-news.laohu8.com/highlight/detail?id=2512900955","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512900955?lang=zh_cn&edition=full","pubTime":"2025-02-18 12:00","pubTimestamp":1739851243,"startTime":"0","endTime":"0","summary":"证券之星消息，美康生物02月17日在投资者关系平台上答复投资者关心的问题。请问公司VAP产品目前开发进度，和市场销售情况如何？公司通过收购取得VAP/VLP血脂亚组分检测技术后，在国内进行技术转化和本土化推广。此外，公司参与2030科技创新“四大慢病”防治研究国家科技重大专项，通过VAP/VLP血脂亚组分检测技术助力血脂“残余风险”的研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021800018311.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300439","BK0239","BK0046","BK0042"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788016775860,"stockEarnings":[{"period":"1week","weight":0.0032},{"period":"1month","weight":0.1102},{"period":"3month","weight":0.028},{"period":"6month","weight":-0.0939},{"period":"1year","weight":-0.1441},{"period":"ytd","weight":-0.0451}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.0323},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0283},{"period":"ytd","weight":-0.0042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"美康生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21165人(较上一季度减少11.00%)","perCapita":"13812股","listingDate":"2015-04-22","address":"浙江省宁波市鄞州区启明南路299号","registeredCapital":"38384万元","survey":" 美康生物科技股份有限公司的主营业务是体外诊断产品的研发、生产和销售及体外诊断产品的代理业务，并提供第三方医学诊断服务。公司的主要产品是体外诊断试剂及仪器、第三方医学诊断服务、智慧实验室整体解决方案。","listedPrice":27.51},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"美康生物(300439)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供美康生物(300439)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"美康生物,300439,美康生物股票,美康生物股票老虎,美康生物股票老虎国际,美康生物行情,美康生物股票行情,美康生物股价,美康生物股市,美康生物股票价格,美康生物股票交易,美康生物股票购买,美康生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"美康生物(300439)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供美康生物(300439)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}